Institutional Ownership
Moonlake Immunotherapeutics
CUSIP 61559X104CLASS A ORDMLTXQ1 2026
13D / 13G Filings
24
Schedule 13D/13G on record
Beneficial Filers
10
Distinct reporting persons
Largest Stake
30.5%
Max % of class reported
Institutional Holders
142
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
24 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Cormorant Asset Management, LP | 13G | 6.1% | 4.36M | SEC |
| 2 | Nov 14, 2025 | Avoro Capital Advisors LLC | 13G/A | 3.1% | 2.00M | SEC |
| 3 | Nov 12, 2025 | Deep Track Capital, LP | 13G | 6.5% | 4.61M | SEC |
| 4 | Nov 10, 2025 | Biotechnology Value Fund L P | 13D/A | 27.7% | — | SEC |
| 5 | Nov 5, 2025 | Fmr LLC | 13G/A | 1.1% | 726.9K | SEC |
| 6 | Oct 1, 2025 | Chen Bihua | 13G/A | 3.1% | 1.99M | SEC |
| 7 | Aug 14, 2025 | Avoro Capital Advisors LLC | 13G | 6.5% | 4.15M | SEC |
| 8 | Aug 6, 2025 | Fmr LLC | 13G/A | 9.0% | 5.70M | SEC |
| 9 | May 14, 2025 | T. Rowe Price Associates, Inc. | 13G/A | 4.7% | 2.97M | SEC |
| 10 | Feb 14, 2025 | T. Rowe Price Associates, Inc. | 13G | 5.3% | 3.34M | SEC |
14 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Moonlake Immunotherapeutics.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Bvf Inc/Il | 16.00M | $298.26M |
| 2 | Deep Track Capital, LP | 6.41M | $119.46M |
| 3 | Cormorant Asset Management, LP | 4.48M | $83.52M |
| 4 | Janus Henderson Group PLC | 3.45M | $64.30M |
| 5 | D. E. Shaw & Co., Inc. | 2.39M | $44.56M |
| 6 | Mpm Bioimpact LLC | 1.81M | $33.76M |
| 7 | Weiss Asset Management LP | 1.71M | $31.84M |
| 8 | Logos Global Management LP | 1.50M | $27.96M |
| 9 | Point72 Asset Management, L.P. | 1.37M | $25.51M |
| 10 | Citadel Advisors LLC | 1.32M | $24.67M |